The Application of Y Series Acceptor-Based Double-Cable Polymers in Single-Material Organic Solar Cells

The development of efficient and stable organic photovoltaic (OPV) systems for commercial applications has long been a primary objective. While single-component material systems have demonstrated promising operational and thermal stability, their efficiency still lags behind that of multicomponent bulk heterojunction devices due to limitations in scarce building blocks, complex synthesis processes, and challenges in controlling morphology. In this work, we present a novel approach by introducing a fused-ring electron acceptor as a pendant segment, which offers new possibilities for the development of double-cable single-component copolymers. This innovative strategy not only broadens their spectral absorption but also simplifies their synthesis complexity. Through careful adjustment of molecular weight, we achieved an outstanding power conversion efficiency of 9.35% and a minimized energy loss of 0.517 eV, which is one of the best results reported for structure well-defined double-cable copolymer-based OPVs. Impressively, the designed double-cable polymers exhibit excellent photo, thermal, and mechanical stabilities, further highlighting their potential for practical applications

Telmisartan PKs of 48 health males with different genotypes.

<p>Data were shown as mean±SD;</p>*<p><i>P</i><0.05; **<i>P</i><0.01.</p><p>PKs, pharmacokinetics; <i>ORM1</i>, orosomucoid 1; <i>ABCC2</i>, ATP-binding cassette, sub-family C, member 2; <i>ABCG2</i>, ATP-binding cassette, sub-family G, member 2; <i>ABCB1,</i> ATP-binding cassette, sub-family B, member 1; <i>SLCO1B3,</i> solute carrier organic anion transporter family, member 1B3; SNP, single nucleotide polymorphisms; AUC_(0–48) the area under the plasma concentration-time curve (AUC) from 0 to 48 h; AUC_(0–∞), AUC from 0 to ∞; C_max, the peak concentration in plasma; CL/F, clearance; T_1/2, elimination half-life; T_max, the time to C_max.</p

Summary of Genetic Variations of SNPs in this Study.

a<p>data published on hapmap; b, data calculated in this study, N = 48; N/A, no data found in hapmap.</p><p>MAF: Minor Allele frequencies; CHB: Han Chinese in Beijing, China; ASW: African ancestry in Southwest USA; CEU: Utah residents with Northern and Western European ancestry from the CEPH collection <i>ORM1</i>, orosomucoid 1; <i>ABCC2</i>, ATP-binding cassette, sub-family C, member 2; <i>ABCG2</i>, ATP-binding cassette, sub-family G, member 2; <i>ABCB1,</i> ATP-binding cassette, sub-family B, member 1; <i>SLCO1B3,</i> solute carrier organic anion transporter family, member 1B3; SNP, single nucleotide polymorphisms; AUC_(0–48) the area under the plasma concentration-time curve (AUC) from 0 to 48 h; AUC_(0–∞), AUC from 0 to ∞; C_max, the peak concentration in plasma; CL/F, clearance; T_1/2, elimination half-life; T_max, the time to C_max.</p

The impacts of <i>ORM1</i> genotypes on the PKs and BP change(%) after 40 mg telmisartan.

<p>A, Concentration; B, AUC_(0–∞); C, SBP change(%) from the baseline; D, DBP change(%) from the baseline.</p

The demographics information of the participants.

<p>BMI, body mass index.</p

The P valve of variable factors on PK and BP change parameters in the corrected models.

<p>Data were shown as mean±SD;</p>*<p><i>P</i><0.05;</p>**<p><i>P</i><0.01.</p><p><i>ORM1</i>, orosomucoid 1; <i>ABCC2</i>, ATP-binding cassette, sub-family C, member 2; <i>ABCG2</i>, ATP-binding cassette, sub-family G, member 2; <i>ABCB1,</i> ATP-binding cassette, sub-family B, member 1; <i>SLCO1B3,</i> solute carrier organic anion transporter family, member 1B3; AUC_(0–∞) the area under the plasma concentration-time curve(AUC) from 0 to ∞; C_max, the peak concentration in plasma; CL/F, clearance; T_1/2, elimination half-life; T_max, the time to C_max; SBP, systolic blood pressure; DBP, diastolic blood pressure.</p

The impacts of <i>ABCC2</i> genotypes on the PKs and BP change(%) after 40 mg telmisartan.

<p>A, Concentration; B, AUC_(0–∞); C, SBP change(%) from the baseline; D, DBP change(%) from the baseline.</p

The significance affected by time or genotypes on the BP change(%) from the baseline.

*<p><i>P</i><0.05;</p><p><i>ORM1</i>, orosomucoid 1; <i>ABCC2</i>, ATP-binding cassette, sub-family C, member 2; SBP, systolic blood pressure; DBP, diastolic blood pressure; Time, the time point in this study including 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 24, 48 h after taking telmisartan.</p